Concourse Financial Group Securities, Inc. An2 Therapeutics, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.64 Billion
- Q3 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ANTX
# of Institutions
33Shares Held
13.5MCall Options Held
0Put Options Held
0-
Bml Capital Management, LLC Zionsville, IN5.75MShares$6.15 Million3.62% of portfolio
-
Ra Capital Management, L.P. Boston, MA2MShares$2.14 Million0.03% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA1.56MShares$1.66 Million0.22% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.04MShares$1.11 Million0.0% of portfolio
-
Acuitas Investments, LLC446KShares$476,9870.23% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $20.8M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...